Phase II study of implantation of carmustine wafers, followed by radiation therapy and concomitant temozolomide and bevacizumab for newly diagnosed glioblastoma.

Trial Profile

Phase II study of implantation of carmustine wafers, followed by radiation therapy and concomitant temozolomide and bevacizumab for newly diagnosed glioblastoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Temozolomide (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms RADICAL TRIAL
  • Most Recent Events

    • 03 Nov 2017 Planned number of patients changed from 55 to 47.
    • 28 May 2017 Status changed from not yet recruiting to recruiting.
    • 18 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top